Systemic lupus erythematosus biomarkers: the challenging quest

Cristina Arriens, Jonathan D. Wren, Melissa E. Munroe, Chandra Mohan

Research output: Contribution to journalReview articlepeer-review

69 Scopus citations


SLE, a multisystem heterogeneous disease, is characterized by production of antibodies to cellular components, with activation of both the innate and the adaptive immune system. Decades of investigation of blood biomarkers has resulted in incremental improvements in the understanding of SLE. Owing to the heterogeneity of immune dysregulation, no single biomarker has emerged as a surrogate for disease activity or prediction of disease. Beyond identification of surrogate biomarkers, a multitude of clinical trials have sought to inhibit elevated SLE biomarkers for therapeutic benefit. Armed with new -omics technologies, the necessary yet daunting quest to identify better surrogate biomarkers and successful therapeutics for SLE continues with tenacity.

Original languageEnglish (US)
Pages (from-to)i32-i45
JournalRheumatology (Oxford, England)
Issue number1
StatePublished - Apr 1 2017


  • antibody.
  • autoimmunity
  • biomarkers
  • chemokine
  • complement
  • cytokine
  • immunosuppressants
  • interleukin
  • lupus nephritis
  • systemic lupus erythematosus

ASJC Scopus subject areas

  • Rheumatology
  • Pharmacology (medical)


Dive into the research topics of 'Systemic lupus erythematosus biomarkers: the challenging quest'. Together they form a unique fingerprint.

Cite this